ALK and non-small cell lung carcinoma: In a retrospective study, median progression-free survival (PFS) on pemetrexed-inclusive regimens was 19 months in RET-rearranged NSCLC, comparable to historical data from patients with tumors harboring ALK or ROS1 fusions [105].